Stock·NASDAQ·Healthcare
Moderna Inc. (MRNA)
- Market cap
- $87.04B
- Dividend yield
- 0.00%
- Street target
- $125.00median of 23 analysts
- 52-week range
- $22.28 $242.29
The short version
Where MRNA stands today, in four lines, and what CleaRank Financial AI makes of it.
MRNA at a glance
Moderna Inc. (MRNA): Hold, 58/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($154.93 and $77.40).
- Earnings MRNA beat estimates in 5 of its last 6 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $64.6M and made no open-market purchases over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
Moderna Inc. (MRNA) earns a Hold rating from CleaRank, with a model score of 58/100.
Trend is the strongest lift: the price is 181.68% above its 200-day average and 40.71% above its 50-day average, while the 50-day average is 100.18% above the 200-day. Valuation is the largest drag, since the company has no meaningful P/E because it lost money and the P/S of 42.38 is 1,146.5% above the sector median. The 50-day average is $154.93 and the 200-day is $77.40, and the price rose 703.28% over the past year.
Only on CleaRank
Figures we compute ourselves from MRNA's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $218.01 is 40.7% above the 50-day simple moving average of $154.93.Price above its 200-day average ›
The price is 181.7% above the 200-day simple moving average of $77.40.50-day average above the 200-day ›
The 50-day average ($154.93) is 100.2% above the 200-day average ($77.40), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 89% of its 52-week range, between $22.28 and $242.29.
MRNA share price
Pick a period: each tab shows how far MRNA has moved over it, to the last close.
Today's trading
Where MRNA sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 42.38 is 1,146.4% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-3.2B on revenue of $2.2B, a net margin of -141.4%.Beat estimates in most recent reports ›
MRNA beat the EPS estimate in 5 of its last 6 reports.
Key statistics
The headline figures for MRNA.
As of October 17, 2026, MRNA trades at $218.01, with a market value of $87.04B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of MRNA's valuation, growth and risks.
A P/E cannot be read for Moderna Inc. (MRNA): it is not meaningful, because the company lost money over the last 12 months. MRNA trades at 42.38 times its sales, 1,146.5% above the sector median of 3.4. The company has a market capitalisation of $87.0B and trailing earnings of -$8.35 a share.
Moderna is still losing money, with a net margin of -141.43% and an operating margin of -557.93%. Revenue growth of 2.10% trails the sector median of 8.1% by 6.0 percentage points. Return on equity of -39.00% sits below the sector median of 7.3%, and debt-to-equity of 0.19 rounds out the balance sheet picture.
For the July 31, 2026 report, Moderna reported -$1.97 a share versus an estimate of -$2.06, beating it by 4.37%. In the first session after the report, the share price moved up 0.58%.
The earnings record shows 5 beats in 6 reports, but beats have not guaranteed gains: the stock fell the next day after 1 of them. Analysts' average EPS estimate for this fiscal year is -$8.39, and -$4.78 for next year.
Normal swings for MRNA run at about 5.30% a day.
MRNA against the Healthcare sector
How MRNA compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, MRNA trades at 42.38x, far above the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, MRNA has gained 792.4% against a gain of 31.6% for XLV.
Performance against XLV
MRNA and the Healthcare sector fund over the same days.
Revenue and earnings
How much MRNA sells, and how much of it becomes profit.
Revenue growth: Revenue fell 39.9% in FY2025 to $1.9B, from $3.2B a year earlier.
Profit margin: The net margin was -146.8% in FY2025, down from -111.3% the year before.
Loss-making: MRNA lost $2.8B in FY2025.
Earnings reality check
Did MRNA beat what analysts expected, and how did the stock react?
Earnings record: MRNA beat the analyst estimate in 5 of the last 6 quarters.
Market reaction: The stock fell in the first session after 1 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 31, 2026after close | -$2.06 | -$1.97 | +4.37% | +0.58% | +7.94% |
| Nov 6, 2025after close | -$2.18 | -$0.51 | +76.61% | +0.86% | +2.59% |
| Aug 1, 2025after close | -$2.97 | -$2.13 | +28.28% | +0.13% | -5.38% |
| May 1, 2025after close | -$3.18 | -$2.52 | +20.75% | +2.15% | -9.80% |
| Feb 14, 2025after close | -$2.76 | -$2.91 | -5.43% | +8.37% | +2.76% |
| Nov 7, 2024after close | -$1.93 | $0.03 | +101.55% | -6.86% | -20.90% |
As of October 17, 2026, MRNA has beaten the analyst EPS estimate in 5 of its last 6 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 31, 2026, came in 4.37% above the estimate and the stock moved +0.58% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 61.7, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 61.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of MRNA
The score, the reasoning behind it, and what could move the price next.
Moderna Inc. (MRNA) is trending up. The stock changes hands at $218.01, which puts it 40.71% above its 50-day average of $154.93 and 181.68% above its 200-day average of $77.40. Near the top of its 52-week range, the price is 10.02% below the $242.29 high and 878.50% above the $22.28 low. A 50-day average 100.18% above the 200-day points the same way as the price, supporting the move instead of undercutting it.
The 14-day RSI of 61.7 is in the bullish zone, below the overbought line, and the MACD line is positive. The price is up over each of these periods: 49.71% over the past month, 252.65% over the past three months and 703.28% over the past year.
Earnings beat ›
The July 31, 2026 report beat the EPS estimate by 4.37%, and the share price rose 0.58% in the first session after it.
Source: Earnings report, July 31, 2026
Analyst downgrade ›
Citigroup downgraded it to Sell from Neutral on September 30, 2026.
Source: Analyst action, Citigroup, September 30, 2026Analyst downgrade ›
Rothschild & Co downgraded it to Sell from Neutral on September 3, 2026.
Source: Analyst action, Rothschild & Co, September 3, 2026
- The two levels to track are the 52-week high at $242.29, which sits above the price, and the 20-day EMA at $199.19, which sits below it.
- A 14-day RSI of 61.7 lands in the bullish zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- The share price rose 0.58% in the first session after the July 31, 2026 report. Over the last 6 reports, MRNA beat estimates in 5 of them.
The uptrend rests on MRNA staying above its 50-day average at $154.93 and its 200-day average at $77.40; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $199.19.
Moderna Inc. (MRNA) has the 52-week high of $242.29 as its next level overhead. The RSI sits in the bullish zone, so momentum still supports the move.
Technical indicators
Momentum and trend for MRNA, from its daily closes.
As of October 17, 2026, with MRNA at $218.01, its 14-day RSI is 61.7 (showing bullish momentum without being overbought), its 50-day simple moving average is $154.93 and its 200-day is $77.40.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What MRNA moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, MRNA's 1-year correlation of daily returns is +0.28 with S&P 500 (SPY), +0.26 with Nasdaq 100 (QQQ), +0.25 with Bitcoin (BTC) and +0.21 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
5 of 23 analysts rate it a buy or strong buy, 15 a hold and 3 a sell.Median target above the price ›
The median 12-month target of $125.00 is 42.7% below the price.More buy ratings than three months ago ›
5 of 23 rate it a buy now, against 4 of 23 three months ago.
MRNA Wall Street View
12-month price targets
The price, $218.01, sits above every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Sep 30, 2026 | Citigroup | Downgrade | Sell |
| Sep 3, 2026 | Rothschild & Co | Downgrade | Sell |
| Aug 28, 2026 | Argus Research | Upgrade | Buy |
| Aug 25, 2026 | Wolfe Research | Upgrade | Peer Perform |
| Aug 24, 2026 | Barclays | Maintains | Equal-Weight |
As of October 17, 2026, 23 Wall Street analysts cover MRNA: 5 rate it a buy or strong buy, 15 a hold and 3 a sell or strong sell. Their 12-month price targets range from $45.00 to $200.00, with a median of $125.00, 42.7% below the price of $218.01.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MRNA trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
MRNA moves about 5.3% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MRNA tends to move, against the market and on its own.
The long record
MRNA's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 5.30% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 94.7%, from September 2021 to November 2025; the price is still 48.5% below that peak.Most 1-year holds ended higher ›
48% of 1-year holding periods in the last 8 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in December 2018 is now worth $117,210, against $32,625 in the S&P 500 (SPY).
MRNA Drawdowns & Recovery
As of October 17, 2026, MRNA's worst peak-to-trough fall over the last 8 years with dividends reinvested was -94.7% (September 2021 to November 2025); it is still 48.5% below that peak, and 48% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MRNA in December 2018 is worth now, against the same amount in the S&P 500.
Against the market: MRNA beat the S&P 500 over this period: $117,210 against $32,625.
A $10,000 investment in MRNA in December 2018 would be worth about $117,210 today with dividends reinvested, compared with about $32,625 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MRNA, and which have not.
Strongest month, April: an average of +17.03%, up in 4 of 8 years.
Weakest month, October: an average of -4.46%, up in 3 of 7 years.
This month, October: has averaged -4.46%, up in 3 of 7 years. Past seasonality does not repeat on schedule.
Over the last 8 years, MRNA's strongest calendar month has been April (average +17.03%, up in 4 of 8 years) and its weakest October (average -4.46%, up in 3 of 7 years).
Average return for each calendar month over the last 8 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MRNA, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MRNA today could grow to about $30,111 by 2036 in the base case, with a 90th-percentile outcome near $228,438 and a 10th-percentile outcome around $3,969. Projections are statistical simulations, not guarantees.
MRNA Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $339 for MRNA by 2030 in the base case, from $218 today (1.6x over 4 years). The 10th-percentile path ends near $94.05. These are outcomes of a Monte Carlo simulation run on MRNA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $128 | $243 | $462 | |
| 2028 | $110 | $272 | $673 | |
| 2029 | $100 | $303 | $921 | |
| 2030 | $94.05 | $339 | $1,221 | |
| 2031 | $90.27 | $378 | $1,585 |
Method: a lognormal simulation of MRNA's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. MRNA is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
MRNA insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought MRNA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, MRNA insiders reported 15 open-market sales worth $64.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Sep 15, 2026 | Stephen Hoge
President
|
Sell | 80.6K | $11.7M |
| Sep 15, 2026 | Stephen Hoge
President
|
Option | 152.9K | $1.9M |
| Sep 10, 2026 | James M Mock
Chief Financial Officer
|
Sell | 34.8K | $4.7M |
| Sep 10, 2026 | James M Mock
Chief Financial Officer
|
Option | 19.8K | $614.1K |
| Sep 4, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 11.8K | - |
| Sep 4, 2026 | James M Mock
Chief Financial Officer
|
Grant | 11.8K | - |
| Sep 1, 2026 | Shannon Thyme Klinger
Officer
|
Sell | 3.5K | $485.8K |
| Sep 1, 2026 | Stephen Hoge
President
|
Grant | 9.3K | - |
| Sep 1, 2026 | Shannon Thyme Klinger
Officer
|
Option | 5.6K | $107.5K |
| Sep 1, 2026 | James M Mock
Chief Financial Officer
|
Grant | 2.5K | - |
| Aug 28, 2026 | Stephen Hoge
President
|
Grant | 2.0K | - |
| Aug 28, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| Aug 28, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.1K | - |
| Aug 6, 2026 | Stephane J Bancel
Chief Executive Officer
|
Option | 751.7K | $14.4M |
| Aug 5, 2026 | Stephane J Bancel
Chief Executive Officer
|
Sell | 499.2K | $28.7M |
| Jul 15, 2026 | Stephen Hoge
President
|
Sell | 53.3K | $3.6M |
| Jul 15, 2026 | Stephen Hoge
President
|
Option | 53.3K | $1.0M |
| Jul 2, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Jun 15, 2026 | Stephen Hoge
President
|
Sell | 53.3K | $2.7M |
| Jun 15, 2026 | Stephen Hoge
President
|
Option | 53.3K | $1.0M |
| Jun 5, 2026 | Shannon Thyme Klinger
Officer
|
Option | 15.3K | $107.5K |
| Jun 5, 2026 | James M Mock
Chief Financial Officer
|
Grant | 11.8K | - |
| Jun 4, 2026 | Shannon Thyme Klinger
Officer
|
Sell | 3.5K | $173.6K |
| Jun 1, 2026 | Stephen Hoge
President
|
Grant | 9.3K | - |
| Jun 1, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 2.2K | - |
| Jun 1, 2026 | James M Mock
Chief Financial Officer
|
Grant | 2.5K | - |
| May 28, 2026 | Stephen Hoge
President
|
Grant | 2.0K | - |
| May 28, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| May 28, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.1K | - |
| May 21, 2026 | Noubar Boghos Afeyan
Director
|
Sell | 9.3K | $433.9K |
| May 21, 2026 | Noubar Boghos Afeyan
Director
|
Option | 9.3K | $177.4K |
| May 15, 2026 | Stephen Hoge
President
|
Sell | 53.3K | $2.6M |
| May 15, 2026 | Stephen Hoge
President
|
Option | 53.3K | $1.0M |
| May 1, 2026 | Shah Abbas Hussain
Director
|
Sell | 5.7K | $265.0K |
| Apr 30, 2026 | Sandra Horning
Director
|
Grant | 16.2K | - |
| Apr 30, 2026 | Shah Abbas Hussain
Director
|
Grant | 16.2K | - |
| Apr 30, 2026 | Elizabeth G Nabel
Director
|
Grant | 16.2K | - |
| Apr 30, 2026 | Francois E. Nader
Director
|
Grant | 12.2K | - |
| Apr 30, 2026 | David M Rubenstein
Director
|
Grant | 8.1K | - |
| Apr 30, 2026 | Elizabeth E Tallett
Director
|
Grant | 4.1K | - |
| Apr 2, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Mar 5, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 11.8K | - |
| Mar 5, 2026 | James M Mock
Chief Financial Officer
|
Grant | 11.8K | - |
| Mar 2, 2026 | Shannon Thyme Klinger
Officer
|
Sell | 13.9K | $726.0K |
| Mar 2, 2026 | Shannon Thyme Klinger
Officer
|
Option | 23.9K | $429.9K |
| Feb 27, 2026 | Stephen Hoge
President
|
Grant | 39.8K | - |
| Feb 27, 2026 | James M Mock
Chief Financial Officer
|
Grant | 11.0K | - |
| Feb 23, 2026 | Stephen Hoge
President
|
Sell | 160.0K | $7.8M |
| Feb 23, 2026 | Stephen Hoge
President
|
Option | 160.0K | $3.1M |
| Feb 11, 2026 | Stephane J Bancel
Chief Executive Officer
|
Grant | 11.3K | - |
| Feb 11, 2026 | Stephen Hoge
President
|
Grant | 4.9K | - |
| Feb 11, 2026 | Shannon Thyme Klinger
Officer
|
Grant | 2.6K | - |
| Feb 11, 2026 | James M Mock
Chief Financial Officer
|
Grant | 2.6K | - |
| Jan 5, 2026 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Dec 11, 2025 | Noubar Boghos Afeyan
Director
|
Sell | 23.9K | $703.3K |
| Dec 11, 2025 | Noubar Boghos Afeyan
Director
|
Option | 23.9K | $260.0K |
| Dec 11, 2025 | Stephane J Bancel
Chief Executive Officer
|
Option | 688.1K | $7.5M |
| Dec 9, 2025 | Shah Abbas Hussain
Director
|
Sell | 504 | $13.9K |
| Dec 5, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 47.2K | - |
| Dec 5, 2025 | James M Mock
Chief Financial Officer
|
Grant | 47.2K | - |
| Dec 1, 2025 | Stephen Hoge
President
|
Grant | 652 | - |
| Dec 1, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 233 | - |
| Nov 28, 2025 | Stephen Hoge
President
|
Grant | 2.0K | - |
| Nov 28, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| Nov 28, 2025 | James M Mock
Chief Financial Officer
|
Grant | 1.1K | - |
| Oct 3, 2025 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Oct 2, 2025 | Shah Abbas Hussain
Director
|
Grant | 1.4K | - |
| Aug 29, 2025 | Stephen Hoge
President
|
Grant | 651 | - |
| Aug 29, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 232 | - |
| Aug 28, 2025 | Stephen Hoge
President
|
Grant | 2.0K | - |
| Aug 28, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| Aug 28, 2025 | James M Mock
Chief Financial Officer
|
Grant | 1.1K | - |
| Aug 5, 2025 | David M Rubenstein
Director
|
Grant | 850 | - |
| Jul 3, 2025 | James M Mock
Chief Financial Officer
|
Grant | 1.5K | - |
| Jun 11, 2025 | Shah Abbas Hussain
Director
|
Sell | 312 | $8.7K |
| Jun 6, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| May 30, 2025 | Stephen Hoge
President
|
Grant | 652 | - |
| May 30, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 233 | - |
| May 28, 2025 | Stephen Hoge
President
|
Grant | 2.0K | - |
| May 28, 2025 | Shannon Thyme Klinger
Officer
|
Grant | 1.1K | - |
| May 28, 2025 | James M Mock
Chief Financial Officer
|
Grant | 1.1K | - |
| Apr 30, 2025 | Sandra Horning
Director
|
Grant | 979 | - |
| Apr 30, 2025 | Shah Abbas Hussain
Director
|
Grant | 892 | - |
| Apr 30, 2025 | Elizabeth G Nabel
Director
|
Grant | 979 | - |
| Apr 30, 2025 | David M Rubenstein
Director
|
Grant | 677 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.